Integrin Activation to Augment SARS-CoV-2 Vaccination

摘要 2020年3月11日，世界卫生组织（世卫组织）宣布了一项全球冠状病毒 2019冠状病毒病（COVID-19）疫情。这种疾病的特点是严重的流感样症状， 高龄（> 65岁）是SARS-CoV-2诱导死亡的重要危险因素。电流 临床阶段的CoV-2疫苗计划必须包括这一重要和脆弱的人群， 他们的初步测试，并产生快速的抗体和细胞特异性反应，以打击 疾病整合素活化化合物是免疫调节剂，其可以增强生产力。 疫苗抗原的反应;我们的初步数据使我们有很强的信心，他们可能是 在增强冠状病毒（COVID-19）疫苗的有效性方面同样有效，特别是在 老年人口。这项研究将直接检验一种新的、专有的整合素 与SARS-CoV-2刺突蛋白（含RBD结构域）一起递送的激活剂（7HP349） 候选疫苗将产生高滴度的中和抗体， 用病毒剂攻击后的结果（中和）。我们的前提是7HP349可以 用作口服免疫激活剂，以增强疫苗的全身免疫力，作为预防工具 来控制SARS-CoV-2的传播。此外，还设想与现有的 不需要抗原重新配制的疫苗。我们的最终目标是改善冠状病毒 负担和随后的COVID-19疾病。

Abstract On March 11, 2020 the World Health Organization (WHO) announced a global Coronavirus Disease 2019 (COVID-19) pandemic. The disease is characterized by severe flu-like symptoms, with advanced age (>65 years) an important risk factor for SARS-CoV-2-induced death. Current clinical stage CoV-2 vaccine programs must include this important and vulnerable population in their initial testing, and generate rapid antibody and cellular specific responses to combat disease. Integrin activating compounds are immune modulators that can potentiate productive responses to vaccine antigens; our preliminary data gives us strong confidence they may be similarly effective in enhancing effectiveness of a coronavirus (COVID-19) vaccine, especially in aged populations. This study will directly test the hypothesis that a novel, proprietary integrin activator (7HP349) delivered with the SARS-CoV-2 spike protein (RBD containing domain) vaccine candidate will generate high titer neutralizing antibodies that will yield protective outcome (neutralization) post challenge with viral agents. Our premise is that 7HP349 can be used as oral immune activator to augment systemic immunity of vaccines as a prophylactic tool to control spread of SARS-CoV-2. It is furthermore envisioned to be used with an existing vaccine without requiring antigen reformulation. Our ultimate goal is to ameliorate coronavirus burden and subsequent COVID-19 disease in both adult and aged individuals.